发展中国家临床诊疗中的N-of-1试验:系统综述
该系统综述检索1985年至2015年9月多个数据库,评估N-of-1试验在发展中国家临床诊疗中的使用程度、目的和结局。共识别131项N-of-1试验,仅6项(4.5%)在发展中国家开展,涉及72名参与者,完成率93%,46名(69%)受试者在试验后依据结果调整用药。作者认为发展中国家N-of-1试验应用少、范围窄,需多方协作提升其应用与质量。
要点
- 发展中国家N-of-1试验极少,仅占已识别试验的4.5%。
- 6项试验中5项在中国开展且均评价中医药。
- 试验后69%受试者依据结果调整用药,完成率93%。
核心结论
- N-of-1试验在发展中国家临床诊疗中的使用率和范围均较低。
- 需政府、临床医生、研究者和资助机构协同提升其应用与质量。
研究设计与样本
- 系统综述检索PubMed、Embase、CINAHL、Web of Science和Cochrane CENTRAL等数据库,覆盖1985年至2015年9月。
- 纳入随机、多周期、个体内交叉的药物干预N-of-1试验,由两名独立评价者进行质量评价和数据提取。
- 共识别131项N-of-1试验,其中6项(4.5%)在发展中国家开展,涉及72名参与者。
主要发现
- N-of-1试验主要用于提供治疗可行性、有效性和安全性的证据。
- 6项试验中5项在中国开展且均评价中医药,另1项在巴西开展。
- 试验完成率为93%,46名(69%)受试者在试验完成后依据结果调整用药。
- 纳入证据存在多种效度威胁,四项研究因缺乏充分药代动力学证据,总体效应估计可能受前一治疗效应「carry over」影响。
临床怎么用
- 在资源有限地区开展N-of-1试验可用于个体化评估药物可行性、有效性和安全性。
- 试验完成后可依据结果调整患者用药,但需注意交叉设计中的 carry over 偏倚。
局限性
- 发展中国家N-of-1试验数量少、范围窄,证据有限。
- 纳入证据存在效度威胁,尤其四项研究缺乏药代动力学证据,总体效应可能受 carry over 影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: N-of-1 trials have a potential role in promoting patient-centered medicine in developing countries. However, there is limited academic literature regarding the use of N-of-1 trials in the clinical care of patients in resource-poor settings. OBJECTIVE: To assess the extent of use, purpose and treatment outcome of N-of-1 trials in developing countries. METHOD: A systematic review of clinical N-of-1 trials was conducted between 1985 and September 2015 using PubMed, Embase, CINAHL, Web of Science and the Cochrane Central Register of Controlled Trials. Grey literature databases and clinical trial registers were also searched. This review included randomized, multi-cycle, crossover within individual patient trials involving drug intervention. Quality assessment and data extraction were conducted by two independent reviewers. RESULT: Out of 131 N-of-1 trials identified, only 6 (4.5%) were conducted in developing countries. The major reason that N-of-1 trials were used was to provide evidence on feasibility, effectiveness and safety of therapies. A total of 72 participants were involved in these trials. Five of the studies were conducted in China and all evaluated Chinese traditional medicine. The remaining study was conducted in Brazil. The completion rate was 93%. More than half, 46 (69%) of subjects made medication changes consistent with trial results after trial completion. A number of threats to the validity of the included evidence limited the validity of the evidence. In particular, the estimated overall effect in four of the included studies could have been affected by the "carry over" of the previous treatment effect as no adequate pharmacokinetic evidence regarding traditional medicines was presented. CONCLUSION: The prevalence and scope of N-of-1 trials in developing countries is low. A coordinated effort among government, clinicians, researchers and sponsor organizations is needed to increase their uptake and quality in developing countries. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015026841 .
引用
- Alemayehu C, Nikles J, Mitchell G, et al. N-of-1 trials in the clinical care of patients in developing countries: a systematic review. Trials. 2018. PMID: 29685163. doi:10.1186/s13063-018-2596-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。